Financial Performance Overview
Mankind Pharma, a leading player in the pharmaceutical sector, recently released its Q3 financial results for the period ending December 31, 2024. The company reported a 16.5% decline in net profit, falling to ₹384 crore from ₹460 crore in the same quarter last year. This decline was primarily due to increased expenses, including costs related to the acquisition of Bharat Serums and Vaccines in October 2024.
Despite the profit decline, the company saw a strong revenue growth of 24%, with revenue from operations rising to ₹3,230 crore from ₹2,607 crore year-over-year. This surge is largely driven by an increased market share in chronic illness drugs, which grew to 37.6% from 35.6%.
The company's market capitalization stands at ₹99,640 crore, with a P/E ratio of 45.16.
Technical Analysis & Trading Outlook
Current Market Price (CMP): ₹2,415.05
Chart Pattern: The stock recently formed a falling wedge pattern on the daily time frame (TF) and gave a breakout with a significant volume increase of 2.36M.
Breakout Confirmation: If the price closes above ₹2,442, we can expect a strong bullish move.
Upside Targets Post-Breakout:
Potential Downside & Reversal Zone
If the price experiences a pullback, we can expect a reversal zone between ₹2,253 - ₹2,336. A bounce from this level could trigger bullish momentum, offering an ideal re-entry point for traders.
With strong revenue growth, technical breakout confirmation, and a well-defined support zone, Mankind Pharma remains a stock to watch for both fundamental investors and technical traders.
Disclaimer: This analysis is for educational purposes only. Investors should conduct their own research before making any trading decisions.
Mankind Pharma, a leading player in the pharmaceutical sector, recently released its Q3 financial results for the period ending December 31, 2024. The company reported a 16.5% decline in net profit, falling to ₹384 crore from ₹460 crore in the same quarter last year. This decline was primarily due to increased expenses, including costs related to the acquisition of Bharat Serums and Vaccines in October 2024.
Despite the profit decline, the company saw a strong revenue growth of 24%, with revenue from operations rising to ₹3,230 crore from ₹2,607 crore year-over-year. This surge is largely driven by an increased market share in chronic illness drugs, which grew to 37.6% from 35.6%.
The company's market capitalization stands at ₹99,640 crore, with a P/E ratio of 45.16.
Technical Analysis & Trading Outlook
Current Market Price (CMP): ₹2,415.05
Chart Pattern: The stock recently formed a falling wedge pattern on the daily time frame (TF) and gave a breakout with a significant volume increase of 2.36M.
Breakout Confirmation: If the price closes above ₹2,442, we can expect a strong bullish move.
Upside Targets Post-Breakout:
- Short-term Target: ₹2,610
- Medium-term Target: ₹2,750
- Long-term Target: ₹3,002
Potential Downside & Reversal Zone
If the price experiences a pullback, we can expect a reversal zone between ₹2,253 - ₹2,336. A bounce from this level could trigger bullish momentum, offering an ideal re-entry point for traders.
With strong revenue growth, technical breakout confirmation, and a well-defined support zone, Mankind Pharma remains a stock to watch for both fundamental investors and technical traders.
Disclaimer: This analysis is for educational purposes only. Investors should conduct their own research before making any trading decisions.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.